SCHEMBL27834997

SCHEMBL27834997

Nc1c(I)ccnc1C1CCCCC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDO2 P48775 3/20 0.37
▸ CYP11B2 P19099 1/20 0.33
▸ HRH2 P25021 1/20 0.32
▸ HRH3 Q9Y5N1 1/20 0.32
▸ BACE1 P56817 1/20 0.32
▸ DGAT1 O75907 1/20 0.31
▸ JAK2 O60674 2/20 0.31
▸ JAK1 P23458 2/20 0.31
▸ TYK2 P29597 2/20 0.31
▸ JAK3 P52333 1/20 0.31
▸ AURKA O14965 1/20 0.31
▸ PRKCA P17252 1/20 0.31
▸ KDR P35968 1/20 0.31
▸ FLT3 P36888 1/20 0.31
▸ NPC1 O15118 2/20 0.31
▸ RAB9A P51151 2/20 0.31
▸ SMN1; SMN2 Q16637 2/20 0.31
▸ TDP1 Q9NUW8 1/20 0.31
▸ L3MBTL1 Q9Y468 1/20 0.31
▸ LMNA P02545 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15740601 0.83 TDO2 (0.36) TDO2CYP11B2HRH2HRH3BACE1
SCHEMBL30385681 0.81 TDO2 (0.34) TDO2CYP11B2HRH2HRH3BACE1
SCHEMBL15740688 0.81 TDO2 (0.34) TDO2CYP11B2HRH2HRH3BACE1
SCHEMBL15740579 0.77 NCF1 (0.32) TDO2NPC1RAB9ASMN1; SMN2LMNA
SCHEMBL27722066 0.73 TDO2 (0.35) TDO2CYP11B2HRH2HRH3BACE1
SCHEMBL927943 0.72 NCF1 (0.34) HRH3SMN1; SMN2LMNAOPRL1
SCHEMBL29012931 0.72 FFAR2 (0.44) TDO2HRH2HRH3NPC1RAB9A
SCHEMBL30154966 0.72 NOS2 (0.52) LMNAOPRL1
SCHEMBL1971040 0.72 NOS2 (0.52) LMNAOPRL1
SCHEMBL2355700 0.71 CYP11B2 (0.40) TDO2CYP11B2HRH2HRH3JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102137856-A 2, 4' -bipyridine compounds as protein kinase D inhibitors useful for the treatment of IA heart failure and cancer NOVARTIS AG 2011-07-27 — — CN disclosed
Send feedback